Accelrys Adds Laboratory Information Management System to Software Suite
The process-driven system reduces total cost of ownership.
The Accelrys Process Management and Compliance Suite has been expanded with the addition of the Accelrys Laboratory Information Management System (LIMS), the company announced in a press release. This system uses a process-driven approach, which focuses on laboratory, quality-control, and manufacturing processes, in contrast to the sample-driven approach used by traditional LIMS. This process-driven approach enables organizations to achieve repeatability and consistency of procedures, automatically qualify operational changes, and maintain a lower total cost of ownership.
"Traditional systems deployed to support laboratory operations today lack the flexibility to manage the change inherent in the hand-off between departments that drive the scientific innovation cycle," said IDC Health Insights Research Director Alan Louie, PhD., in the press release. "By coming at LIMS from the process execution standpoint, companies like Accelrys are taking a more holistic approach to managing data. This approach is well suited for lab operations that are trying to drive standardization across changing environments while still maintaining process repeatability and regulatory compliance."
The Accelrys LIMS integrates with Accelrys Electronic Laboratory Notebook (ELN), Accelrys Laboratory Execution System (LES), Accelrys Electronic Batch Records (EBR), Accelrys Discoverant process management informatics, and the Accelrys Enterprise Platform (AEP) for data exchange to provide an end-to-end informatics system that makes data accessible across an organization.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
